



Rethinking Your Breast Biopsy System

Improving the stereotactic breast biopsy procedure through decreased operating time¹ and enhanced sample collection

As Director of Breast Imaging Services at Franciscan Health, Dr. Madelyn Lefranc has performed stereotactic core biopsies for the past 20 years. Having used a variety of biopsy systems throughout her career, Dr. Lefranc prefers Hologic's Brevera® Breast Biopsy System due to its contributions to patient comfort, advanced tissue handling, and reduced procedure time¹.



Madelyn Lefranc, MD
Radiology Partners
Franciscan Health
Lafayette, Indiana

For more information, contact your Hologic representative

breverabiopsy.com

Decreased Operating Time¹

The Brevera breast biopsy system features innovative imaging technology to combine tissue acquisition, real-time imaging, verification, and advanced tissue handling to support an optimal procedure. The system's real-time imaging allows for the immediate verification of excised tissue while the high-resolution touchscreen monitor and built-in image enhancement tools allow the user to quickly locate and mark faint calcifications. When taken together, these features give the Brevera biopsy system the potential to save an average of 12 minutes per procedure.¹

"The biggest strength of the Brevera biopsy system is the ability to obtain an image of your sample in real time. We no longer need to stop during a biopsy to take the samples to another room for x-ray," said Dr. Lefranc. "The system has decreased the time of our procedures compared to stereotactic core biopsies performed with other systems."

The biopsy system also has remote operation and clinician-controlled sampling, helping to improve speed and efficiency during a biopsy. It features intuitive software that seamlessly integrates into a clinician's workflow. The system can even share images and transfer patient records with PACS integration and wireless connectivity.

Rethinking Tissue Collection

The Brevera breast biopsy system enhances tissue collection using one adjustable needle for both 20mm and 12mm aperture procedures, enabling clinicians to quickly and seamlessly transition from a standard needle to a petite needle for easy sampling.

Clinicians also enjoy little to no manual handling of tissue samples with the Brevera breast biopsy system, reducing the risk of human error while maintaining sample integrity as it moves to pathology. The system is designed to automatically separate and identify samples with the 12-chamber tissue filter, which Dr. Lefranc notes helps provide guidance for her pathology team.

"The tissue collection for the Brevera system has been a great improvement as compared to our prior tissue collection methods," said Dr. Lefranc. "The different cores are put into individual compartments that are labeled. From there, I can direct the pathologist to the ones that are more concerning and can direct their attention to that specific sample."

“The tissue collection for the Brevera system has been a great improvement as compared to our prior tissue collection methods.”





“It was standard for us to take 12 samples during a biopsy; now we take three or four samples because I can clearly see that I am getting what I need. This improves the patient’s experience because it reduces time spent under compression in addition to reducing the potential for bleeding and other complications.”

Improving the Patient Experience

Reducing procedure time and enhancing sample collection could improve the patient’s experience, something that Dr. Lefranc has noticed. “I have patients that have undergone stereotactic core biopsies from before we introduced the Brevera biopsy system and after. They do notice the difference,” said Dr. Lefranc. “We have been able to ease some of their anxiety around biopsies as a result of the Brevera procedure being that much quicker and easier.”

The Brevera system is designed to improve core retrieval while also minimizing incision size². Dr. Lefranc noticed that with real-time visualization, she was able to take less tissue, in turn, reducing the potential for procedure complications.

“Compared to our previous process, we have decreased the number of samples we need with the Brevera breast biopsy system,” said

Dr. Lefranc. “It was standard for us to take 12 samples during a biopsy; now we take three or four samples because I can clearly see that I am getting what I need. This improves the patient’s experience because it reduces time spent under compression in addition to reducing the potential for bleeding and other complications.”

The Brevera breast biopsy system with CorLumina® imaging technology can improve stereotactic biopsy procedures for the radiologist, pathologist, and most importantly, the patient—something that Dr. Lefranc has found to be immensely beneficial. “The Brevera system has changed my practice for the better. I have other radiologists ask me, ‘what do you think about the Brevera?’ And I say, come to our breast center and use it. It makes a huge difference in our practice.”



Brevera®
Breast Biopsy System

¹ Brevera Pulse Survey Quantitative report. Inspired Insights. April 2019

² Hologic data on file, Compared with Mammotome Revolve® 8G.

CS-00371 Hologic, Inc. ©2023 All rights reserved. Hologic, Brevera, CorLumina, The Science of Sure, and associated logos are trademarks and/or registered trademarks of Hologic, Inc., and/or its subsidiaries in the United States and/or other countries. Madelyn Lefranc, MD, is a paid consultant for Hologic. This information is intended for medical professionals in the U.S. and other markets and is not intended as a product solicitation or promotion where such activities are prohibited. Views and opinions expressed herein by the medical professional are theirs alone and do not necessarily reflect those of Hologic. Because Hologic materials are distributed through websites, eBroadcasts and tradeshow, it is not always possible to control where such materials appear. For specific information on what products are for sale in a particular country, please contact your local Hologic representative.

Important Safety Information. The Hologic® Brevera® breast biopsy system with CorLumina® imaging technology is intended to provide breast tissue samples for diagnostic sampling of breast abnormalities. The Brevera breast biopsy system excises targeted tissue and optionally delivers in-line radiographic images of the excised tissue. The Brevera breast biopsy system is intended to provide breast tissue for histologic examination with partial or complete removal of the imaged abnormality. In instances when a patient presents with a palpable abnormality that has been classified as benign through clinical and/or radiological criteria (for example, fibroadenoma, fibrocystic lesion), the Brevera breast biopsy system may also be used to partially remove such palpable lesions. The extent of histologic abnormality cannot be reliably determined from its mammographic appearance. Therefore, the extent of removal of the imaged evidence of an abnormality does not predict the extent of removal of histological abnormality, for example, malignancy. When the sampled abnormality is not histologically benign, it is essential that the tissue margins be examined for completeness of removal using standard surgical procedure.

The Brevera breast biopsy system with CorLumina imaging technology is not intended for therapeutic applications. The Brevera breast biopsy system with CorLumina imaging technology is contraindicated for those patients who, based on the physician’s judgment, may be at increased risk or develop complications associated with core removal or biopsy. Patients receiving anticoagulant therapy or who may have bleeding disorders may be considered at increased risk of procedural complications. For detailed benefit and risk information, please consult the IFU.